Extending Maintenance Dosing Intervals for Guselkumab in the Treatment of Patients With Psoriasis
JAMA Dermatology · 2024
DOI: 10.1001/jamadermatol.2024.2462 ↗Kurz gefasst
Kommentar in der Zeitschrift JAMA Dermatology, 2024. Verfasst von Andrew Blauvelt und 2 weiteren Autor:innen. Beteiligte Einrichtung: Blauvelt Consulting, LLC, Lake Oswego, Oregon. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized, Drug Administration Schedule. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Blauvelt Consulting, LLC, Lake Oswego, Oregon.
- Department of Dermatology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland.
- Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Zitieren
APA
Blauvelt, A., Conrad, C., & Noe, M. H. (2024). Extending Maintenance Dosing Intervals for Guselkumab in the Treatment of Patients With Psoriasis. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2024.2462
Vancouver
Blauvelt A, Conrad C, Noe MH. Extending Maintenance Dosing Intervals for Guselkumab in the Treatment of Patients With Psoriasis. JAMA Dermatology. 2024. doi:10.1001/jamadermatol.2024.2462
BibTeX
@article{Blauvelt2024,
author = {Blauvelt, Andrew and Conrad, Curdin and Noe, Megan H},
title = {Extending Maintenance Dosing Intervals for Guselkumab in the Treatment of Patients With Psoriasis},
journal = {JAMA Dermatology},
year = {2024},
doi = {10.1001/jamadermatol.2024.2462}
}
EUVIMED